HCPLive Network
PERSONAL FINANCE

Celgene Sell Off “Overdone”

Laura Joszt | Friday, June 22, 2012
While Onyx Pharmaceuticals is flying high on good news for its blood cancer drug, Celgene wasn’t quite so lucky. Celgene’s stock took a big hit on Thursday when it withdrew its application for Revlimid. And by the end of the week, the stock hadn’t recovered much.
 
When the European Medicine’s Agency (EMA) indicated it wanted more data on Revlimid’s application to be used on newly diagnosed multiple myeloma patients and as a maintenance therapy, Celgene withdrew the application. When news broke, its stock dropped 11.65% at the opening bell on Thursday.
 
By the end of the day Friday, the stock had only recovered slightly, up 3.68%, but still down by 8.19% over where it had closed on Wednesday afternoon.
 
 
However, investors might be a little trigger happy with Celgene. For one, the company could still resubmit to EMA. Also, a trial combining Onyx’s Kyprolis with Revlimid and Dexa revealed that patients had a 98% response rate and a 92% progression-free survival rate.
 
Revlimid is already an approved blood cancer drug — the company is simply looking to expand its use. Plus, the drug could also have a number of other uses, such as lymphoma and CLL. Another Celgene drug could be approved for a second use this year.
 
According to SeekingAlpha, the sell off could nicely benefit investors who take advantage of it to buy up shares. Robert W. Baird released a note that it believed the sell off was overdone. The wealth management company has set a price target at $78.
 
The information contained in this article should not be construed as investment advice or as a solicitation to buy or sell any stock.
 
Read more:


RELATED ARTICLES
Healthcare practices continue to suffer from embezzlement problems. While there is no such thing as a perfect system to prevent embezzlers, there are ways to deter them.
Most people don’t realize how closely emotions affect financial spending, which can lead to poor decisions and overspending. But knowing potential triggers can help you overcome them in the future.
Medical research funding is critical, but many promising startups never reach clinical stages due to a lack of funds. However, the path has opened up for even the average investor.
RECENT CLINICAL ARTICLES
Even though the active ingredient in marijuana can be associated with memory impairment, it may slow or halt Alzheimer’s disease.
A prognostic model has been developed and validated which has adequate discrimination for major outcomes in type 1 diabetes, according to a study published online Aug. 28 in Diabetologia.
For patients with cancer, factors associated with late admission to hospice have been identified, according to a study published online Aug. 25 in the Journal of Clinical Oncology.